World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)

July 2010 | 230 pages | ID: W6B136A2075EN
Kalorama Information

Abstracts

ProdUnitPrice (Single User PDF): US$ 4.500,00
ProdUnit Price (Global Site License): US$ 9.000,00

What Will The Pharmaceutical Market Look Like in the Next Five Years?

This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in pharmaceuticals, the companies that produce the lion's share of revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of companies and the lines between pharmaceutical and biotechnology specialty companies are becoming more blended; which is a trend expected to continue to grow.

This Kalorama Information market research report, The World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.

Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Potential Market Opportunity

Issues and Trends Affecting Market

Leading Companies

CHAPTER TWO: INTRODUCTION

Global Pharmaceutical Market

Pharmaceutical Research & Development Overview

Clinical Trial Costs

CHAPTER THREE: ISSUES AND TRENDS

Biotechnology Drug Development

Orphan Drugs

Fast Track Drug Status

Other Accelerated Methods for Drug Approval

Pharmaceutical Regulatory Exclusivity

Pediatric Extensions

Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation

Aging Population

Mergers, Acquisitions, and Collaborations

Contributors To R&D Success

R&D Spending

The Role of Contract Research Organizations

Sustainability in a changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

Introduction

Pfizer, Inc./Wyeth (merged in 2009)

Overview

Financial Performance and Investments

Late Stage Pipeline

Merck & Co., Inc.

Overview

Financial Performance and Investments

Late Stage Pipeline

Novartis AG

Overview

Financial Performance and Investments

Late Stage Pipeline

Roche Ltd.

Overview

Financial Performance and Investments

Late Stage Pipeline

Sanofi-Aventis

Overview

Financial Performance and Investments

Late Stage Pipeline

AstraZeneca plc

Overview

Financial Performance and Investments

Late Stage Pipeline

GlaxoSmithKline plc

Overview

Financial Performance and Investments

Late Stage Pipeline

Johnson & Johnson

Overview

Financial Performance and Investments

Late Stage Pipeline

Eli Lilly & Company

Overview

Financial Performance and Investments

Late Stage Pipeline

Bristol-Myers Squibb Company

Overview

Financial Performance and Investments

Late Stage Pipeline

Abbott Laboratories

Overview

Financial Performance and Investments

Late Stage Pipeline

Takeda Pharmaceutical Co., Ltd.

Overview

Financial Performance and Investments

Late Stage Pipeline

Bayer AG

Overview

Financial Performance and Investments

Late Stage Pipeline

Amgen, Inc.

Overview

Financial Performance and Investments

Late Stage Pipeline

Boehringer Ingelheim GmbH

Overview

Financial Performance and Investments

Late Stage Pipeline

TEVA Pharmaceutical Industries, Ltd.

Overview

Financial Performance and Investments

Late Stage Pipeline

Astellas

Overview

Financial Performance and Investments

Late Stage Pipeline

Daiichi Sankyo

Overview

Financial Performance and Investments

Late Stage Pipeline

Novo Nordisk

Overview

Financial Performance and Investments

Late Stage Pipeline

Eisai

Overview

Financial Performance and Investments

Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST

Introduction

Otsuka

Late Stage Pipeline

Merck KGaA

Late Stage Pipeline

Gilead Sciences

Late Stage Pipeline

Mylan

Pipeline

Baxter International

Late Stage Pipeline

Chugai Pharmaceutical Company, Ltd.

Late Stage Pipeline

Mitsubishi Tanabe

Late Stage Pipeline

Servier, Les Laboratories

Pipeline

UCB SA

Late Stage Pipeline

Allergan

Late Stage Pipeline

Forest Laboratories

Late Stage Pipeline

Nycomed International

Late Stage Pipeline

Genzyme Corporation

Late Stage Pipeline

Biogen Idec

Late Stage Pipeline

Hospira

Late Stage Pipeline

Watson

Pipeline

CSL Limited

Late Stage Pipeline

Alcon

Late Stage Pipeline

Shire

Late Stage Pipeline

Celgene Corporation

Late Stage Pipeline

Lundbeck

Late Stage Pipeline

Shionogi & Co., Ltd.

Late Stage Pipeline

Menarini Group

Late Stage Pipeline

Dainippon Sumitomo Pharma, Co., Ltd.

Late Stage Pipeline

Cephalon

Late Stage Pipeline

Actelion

Late Stage Pipeline

Procter & Gamble

Endo Pharmaceuticals

Late Stage Pipeline

Ono Pharmaceutical Co.

Late Stage Pipeline

Purdue Pharma

Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST

Overview

Company Analysis

Pipeline Snapshot: Top 50 Companies

Current Market Value

Market Forecast

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET

Biopharmaceutical Companies

Biopharmaceutical Market Forecast

APPENDIX: LIST OF COMPANIES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)

Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated

CHAPTER TWO: INTRODUCTION

Table 2-1: Phases of Clinical Drug Development

Table 2-2: Components of a Clinical Trial

CHAPTER THREE: ISSUES AND TRENDS

Table 3-1: International Population Trend Age 65+

Figure 3-1: International Population Trend Age 65+

Table 3-2: United States Population Trend Age 65+

Figure 3-2: International Population Trend Age 65+

Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions

Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics

Figure 3-3: Drug Development Cost Progression

Table 3-5: Total Industry R&D Spending 2004-2009

Figure 3-4: Total Industry R&D Spending 2004-2009

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)

Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-3: Pfizer’s Late Stage Product Pipeline

Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area

Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-3: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-5: Merck & Co.’s Late Stage Product Pipeline

Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area

Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-5: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-7: Novartis’ Late Stage Product Pipeline

Figure 4-6: Novartis’ Late Stage Product Pipeline by Therapeutic Area

Table 4-8: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-7: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-9: Roche’s Late Stage Product Pipeline

Figure 4-8: Roche’s Late Stage Product Pipeline by Therapeutic Area

Table 4-10: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-9: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-11: Sanofi-Aventis’ Late Stage Product Pipeline

Figure 4-10: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area

Table 4-12: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-11: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-13: AstraZeneca’s Late Stage Product Pipeline

Figure 4-12: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area

Table 4-14: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-13: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-15: GlaxoSmithKline’s Late Stage Product Pipeline

Figure 4-14: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area

Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-15: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline

Figure 4-16: Johnson & Johnson’s Late Stage Product Pipeline by Therapeutic Area

Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-17: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009

Table 4-19: Eli Lilly’s Late Stage Product Pipeline

Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area

Table 4-20: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-19: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-21: Bristol-Myers Squibb’s Late Stage Product Pipeline

Figure 4-20: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area

Table 4-22: Abbott’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-21: Abbott’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-23: Abbott’s Late Stage Product Pipeline

Figure 4-22: Abbott’s Late Stage Product Pipeline by Therapeutic Area

Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2009 (Millions)

Figure 4-23: Takeda’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline

Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area

Table 4-26: Bayer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-25: Bayer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-27: Bayer’s Late Stage Product Pipeline

Figure 4-26: Bayers’ Late Stage Product Pipeline by Therapeutic Area

Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-27: Amgen’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-29: Amgen’s Late Stage Product Pipeline

Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area

Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-29: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline

Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area

Table 4-32: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Figure 4-31: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions)

Table 4-33: TEVA’s Late Stage Product Pipeline Figure 4-32: TEVA’s Late Stage Product Pipeline by Therapeutic Area

Table 4-34: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions)

Figure 4-33: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions)

Table 4-35: Astellas’ Late Stage Product Pipeline

Figure 4-34: Astellas’ Late Stage Product Pipeline by Therapeutic Area

Table 4-36: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)

Figure 4-35: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)

Table 4-37: Daiichi Sankyo’s Late Stage Product Pipeline

Figure 4-36: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area

Table 4-38: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)

Figure 4-37: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)

Table 4-39: Novo Nordisk’s Late Stage Product Pipeline

Figure 4-38: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area

Table 4-40: Eisai’s Total Company Revenue and R&D Spending 2007-2009 (Thousands)

Figure 4-39: Eisai’s Total Company Revenue and R&D Spending 2007-2009

Table 4-41: Eisai’s Late Stage Product Pipeline

Figure 4-40: Eisai’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER FIVE: COMPANIES OF INTEREST

Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales

Table 5-2: Otsuka Pharmaceutical’s Late Stage Product Pipeline

Figure 5-1: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area

Table 5-3: Merck KGaA’s Late Stage Product Pipeline

Figure 5-2: Merck KGaA’s Late Stage Product Pipeline by Therapeutic Area

Table 5-4: Gilead Sciences’ Late Stage Product Pipeline

Figure 5-3: Gilead Sciences’ Late Stage Product Pipeline by Therapeutic Area

Table 5-5: Baxter International’s Late Stage Product Pipeline

Figure 5-4: Baxter International’s Late Stage Product Pipeline by Therapeutic Area

Table 5-6: Chugai Pharmaceutical’s Late Stage Product Pipeline

Figure 5-5: Chugai’s Late Stage Product Pipeline by Therapeutic Area

Table 5-7: Mitsubishi Tanabe’s Late Stage Product Pipeline

Figure 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline by Therapeutic Area

Table 5-8: UCB Pharma’s Late Stage Product Pipeline

Figure 5-7: UCB’s Late Stage Product Pipeline by Therapeutic Area

Table 5-9: Allergan’s Late Stage Product Pipeline

Figure 5-8: Allergan’s Late Stage Product Pipeline by Therapeutic Area

Table 5-10: Forest Laboratories’ Late Stage Product Pipeline

Figure 5-9: Forest Laboratories’ Late Stage Product Pipeline by Therapeutic Area

Table 5-11: Nycomed’s Late Stage Product Pipeline

Figure 5-10: Nycomed’s Late Stage Product Pipeline by Therapeutic Area

Table 5-12: Genzyme’s Late Stage Product Pipeline

Figure 5-11: Genzyme’s Late Stage Product Pipeline by Therapeutic Area

Table 5-13: Biogen Idec’s Late Stage Product Pipeline

Figure 5-12: Biogen Idec’s Late Stage Product Pipeline by Therapeutic Area

Table 5-14: Hospira’s Late Stage Product Pipeline

Figure 5-13: Hospira’s Late Stage Product Pipeline by Therapeutic Area

Table 5-15: CSL’s Late Stage Product Pipeline

Figure 5-14: CSL’s Late Stage Product Pipeline by Therapeutic Area

Table 5-16: Alcon’s Late Stage Product Pipeline

Figure 5-15: Alcon’s Late Stage Product Pipeline by Therapeutic Area

Table 5-17: Shire’s Late Stage Product Pipeline

Figure 5-16: Shire’s Late Stage Product Pipeline by Therapeutic Area

Table 5-18: Celgene’s Late Stage Product Pipeline

Figure 5-17: Celgene’s Late Stage Product Pipeline by Therapeutic Area

Table 5-19: Lundbeck’s Late Stage Product Pipeline

Figure 5-18: Lundbeck’s Late Stage Product Pipeline by Therapeutic Area

Table 5-20: Shionogi’s Late Stage Product Pipeline

Figure 5-19: Shionogi’s Late Stage Product Pipeline by Therapeutic Area

Table 5-21: Menarini’s Late Stage Product Pipeline

Figure 5-20: Menarini’s Late Stage Product Pipeline by Therapeutic Area

Table 5-22: Dainippon Sumitomo’s Late Stage Product Pipeline

Figure 5-21: Dainippon Sumitomo’s Late Stage Product Pipeline by Therapeutic Area

Table 5-23: Cephalon’s Late Stage Product Pipeline

Figure 5-22: Cephalon’s Late Stage Product Pipeline by Therapeutic Area

Table 5-24: Actelion’s Late Stage Product Pipeline

Figure 5-23: Actelion’s Late Stage Product Pipeline by Therapeutic Area

Table 5-25: Endo Pharmaceutical’s Late Stage Product Pipeline

Figure 5-24: Endo Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area

Table 5-26: Ono Pharmaceutical’s Late Stage Product Pipeline

Figure 5-25: Ono Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area

Table 5-27: Purdue Pharma’s Late Stage Product Pipeline

Figure 5-26: Purdue Pharma’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER SIX: MARKET FORECAST

Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)

Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)

Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)

Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)

Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)

Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)

Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005-2010

Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)

Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated

Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—Potential Impact from Late-Stage Development

Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact from Late-Stage Development

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET

Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales

Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues

Table 7-3: Biotechnology Late Stage Development Projects by Company Classification—Pharmaceutical vs. Biotechnology--Market Forecast, 2015